The Canberra Hospital

The trials here

What the 19 trials at this site are about, from their registry records.

Conditions

• Myeloproliferative neoplasms2 trials
• Prostate cancer2 trials
• Amyloidosis1 trial
• Asthma1 trial
• Atrial fibrillation1 trial
• Chronic kidney disease1 trial
• COPD1 trial
• Coronary artery disease1 trial
• Crohn's disease1 trial
• Diffuse large B-cell lymphoma1 trial
• Follicular lymphoma1 trial
• Idiopathic pulmonary fibrosis1 trial
• and 5 more

Phase

• Phase 314 trials
• Phase 24 trials

Status

• Completed7 trials
• Not yet recruiting4 trials
• Recruiting4 trials
• Active, not recruiting3 trials
• Withdrawn1 trial

Lead sponsor

• Connect Biopharm LLC2 trials
• Hoffmann-La Roche2 trials
• Janssen Research & Development, LLC2 trials
• Takeda2 trials
• Alliance Foundation Trials, LLC.1 trial
• and 10 more

Running trials

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

  Contact: Philip Choi (principal investigator)

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

  NCT06058585· Phase 3· The George Institute· Source

  Contact: Girish Talaulikar

• Recruiting

  Working Out M0 Bipolar Androgen Therapy

  NCT06594926· Phase 2· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Source

  Contact: Monika Tencic

• Recruiting

  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  NCT06128629· Phase 3· Intellia Therapeutics· Source

  Contact: Trial Manager at Intellia

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

  NCT04332822· Phase 3· Nordic Lymphoma Group· Source

  Contact: Pietro Di Ciaccio

• Recruiting

  Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

  NCT03860883· Melanoma and Skin Cancer Trials Limited· Source

  Contact: Emily Baxter

• Active, not recruiting

  Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

  NCT02947685· Phase 3· Alliance Foundation Trials, LLC.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis1 recruiting
• Chronic kidney disease1 recruiting
• Crohn's disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Melanoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Completed

  Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

  NCT06940154· Phase 2· Connect Biopharm LLC· Source

• Completed

  Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

  NCT06940141· Phase 2· Connect Biopharm LLC· Source

• Completed

  Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

  NCT06331624· Phase 2· GRI Bio Operations, Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347· Phase 3· Pharmacyclics LLC.· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source